We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
52 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Rystiggo has been approved as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Bimzelx bimekizumab 320 mg/2 mL solution for injection auto-injector.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Bimzelx bimekizumab 320 mg/2 mL solution for injection safety syringe.
-
Cancellation by sponsorRequested by UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for RYSTIGGO rozanolixizumab 140 mg/mL solution for injection for infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FINTEPLA fenfluramine 2.2 mg/mL Oral Solution Bottle.
-
Prescription medicine registrationActive ingredients: bimekizumab.
-
Prescription medicine registrationActive ingredients: rozanolixizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZILBRYSQ zilucoplan (as tetrasodium) 16.6 mg/ 0.416 mL solution for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ZILBRYSQ zilucoplan (as tetrasodium) 23.0 mg/ 0.574 mL solution for injection pre-filled syringe.